CORDIS
EU research results

CORDIS

English EN

Alzheimer's disease-treatment targeting truncated Aß40/42 by active immunisation

Project information

Grant agreement ID: 37702

  • Start date

    1 October 2006

  • End date

    31 December 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 4 327 500

  • EU contribution

    € 2 370 155

Coordinated by:

AFFIRIS AG

Austria

Objective

Alzheimer's disease (AD) is the most common form of dementia in humans. According to the Alzheimer Association there are currently 12 million patients worldwide with estimated social costs for every patient reaching 40,000 per year. At present, no effective treatment is available to stop the progressive neuro-degeneration and associated cognitive decline in AD patients. AD is characterized by the abnormal accumulation of amyloid plaques in the brain.

These plaques mainly consist of the Amyloid-(A) peptides Aß40/42 derived from the Amyloid Precursor Protein (APP). Immunotherapeutic treatment targeting Aß led to amyloid plaque reduction and had beneficial impact on disease progression in animal models. However, the first phase II clinical vaccination trial in AD patients using full length Aß42 as antigen had to be discontinued due to severe neuroinflammatory side effects including brain infiltration by autoreactive T-cells. In humans most of the amyloid plaque material is formed by N-terminally truncated and modified Aß derivatives. These truncated Aß species are correlated with increasing severity and early onset of neurodegeneration in AD patients.

In light of the characteristics of amyloid composition in patients, these truncated Aß peptides are highly attractive targets providing neoepitopes not present on parental APP. The Mimotope technology presented in this proposal will be used to create antigens mimicking potentially pathological B-cell epitopes on truncated Aß. A Mimotope-based AD vaccine targeting truncated forms of Aß would therefore induce a safe antibody response exclusively reacting with the pathological Aß molecules but not with parental APP and would avoid the induction of autoreactive T-cells. Thus the MimoVax vaccine will provide an innovative, safe, cost effective and efficient approach to successfully treat AD patients and to limit the severe personal and economic impact of AD on patients, their families and society.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AFFIRIS AG

Address

Campus Vienna Biocenter; Karl-Farkas-Gasse 22
Vienna

Austria

Participants (10)

JSW LIFESCIENCE GMBH

Austria

EUROESPES, S.A.

Spain

EUROESPES, S.A.

Spain

PICHEM RESEARCH& DEVELOPMENT - DR.FRITZ ANDREAE

Austria

PHILIPPS-UNIVERSITAET MARBURG

Germany

TECHNISCHE UNIVERSITÄT MÜNCHEN - KLINIKUM RECHTS DER ISAR

Germany

BIOLUTION GRÜNERT & CO KEG

Austria

PICHEM FORSCHUNGS- UND ENTWICKLUNGSGMBH.

Austria

BIOLUTION GMBH

Austria

EUROESPES MEDICINA, S.L.

Spain

Project information

Grant agreement ID: 37702

  • Start date

    1 October 2006

  • End date

    31 December 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 4 327 500

  • EU contribution

    € 2 370 155

Coordinated by:

AFFIRIS AG

Austria